Vivimed Labs Limited (NSE:VIVIMEDLAB)
India · Delayed Price · Currency is INR 5.50
+0.10 (1.85%)
Nov 11, 2026, 2:58 PM IST
Vivimed Labs Revenue
In the fiscal year ending March 31, 2026, Vivimed Labs had annual revenue of 763.08M INR, down -36.75%. Vivimed Labs had revenue of 177.47M in the quarter ending March 31, 2026, a decrease of -40.51%. That makes Vivimed Labs the 38,266th largest company in the world by revenue and 3,469th in India.
Revenue
763.08M
Revenue Growth
-36.75%
P/S Ratio
0.59
Revenue / Employee
1.30M
Employees
586
Market Cap
456.03M
Revenue by Geography
- India 908.21M 78.1%
- Export 254.48M 21.9%
Fiscal year ended Mar 31, 2025 See the full Vivimed Labs breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 763.08M | -443.32M | -36.75% |
| Mar 31, 2025 | 1.21B | -384.07M | -24.15% |
| Mar 31, 2024 | 1.59B | -290.20M | -15.43% |
| Mar 31, 2023 | 1.88B | -504.90M | -21.16% |
| Mar 31, 2022 | 2.39B | -6.33B | -72.62% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sigachi Industries | 4.91B |
| Valiant Laboratories | 3.76B |
| Amanta Healthcare | 3.04B |
| Balaxi Pharmaceuticals | 2.80B |
| Bafna Pharmaceuticals | 1.43B |
| Alpa Laboratories | 1.11B |
| Vaishali Pharma | 1.08B |
| Par Drugs and Chemicals | 1.08B |